Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Dec;15(12):1750-61.
doi: 10.1093/neuonc/not122. Epub 2013 Sep 17.

Time trends in glioblastoma multiforme survival: the role of temozolomide

Robert Dubrow  1 , Amy S Darefsky, Daniel I Jacobs, Lesley S Park, Michal G Rose, Maxwell S H Laurans, Joseph T King Jr
Affiliations
Comparative Study

Time trends in glioblastoma multiforme survival: the role of temozolomide

Robert Dubrow et al. Neuro Oncol. 2013 Dec.

Abstract

Background: In 2005, maximum safe surgical resection, followed by radiotherapy with concomitant temozolomide (TMZ), followed by adjuvant TMZ became the standard of care for glioblastoma (GBM). Furthermore, a modest, but meaningful, population-based survival improvement for GBM patients occurred in the US between 1999 (when TMZ was first introduced) and 2008. We hypothesized that TMZ usage explained this GBM survival improvement.

Methods: We used national Veterans Health Administration (VHA) databases to construct a cohort of GBM patients, with detailed treatment information, diagnosed 1997-2008 (n = 1645). We compared survival across 3 periods of diagnosis (1997-2000, 2001-2004, and 2005-2008) using Kaplan-Meier curves. We used proportional hazards models to calculate period hazard rate ratios (HRs) and 95% confidence intervals (CIs), adjusted for demographic, clinical, and treatment covariates.

Results: Survival increased over calendar time (stratified log-rank P < .0001). After adjusting for age and Charlson comorbidity score, for cases diagnosed in 2005-2008 versus 1997-2000, the HR was 0.72 (95% CI, 0.64-0.82; p-trend < .0001). Sequentially adding non-TMZ treatment variables (ie, surgery, radiotherapy, non-TMZ chemotherapy) to the model did not change this result. However, adding TMZ to the model containing age, Charlson comorbidity score, and all non-TMZ treatments eliminated the period effect entirely (HR = 1.01; 95% CI, 0.86-1.19; p-trend = 0.84).

Conclusions: The observed survival improvement among GBM patients diagnosed in the VHA system between 1997 and 2008 was completely explained by TMZ. Similar studies in other populations are warranted to test the generalizability of our finding to other patient cohorts and health care settings.

Keywords: brain neoplasms; glioblastoma; survival; temozolomide; time trends.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Kaplan–Meier survival plots according to period of diagnosis. (A) Full cohort (n = 1645). (B) Restricted cohort (treated with resection and radiotherapy) (n = 932).
See this image and copyright information in PMC

References

    1. Clinical Trials and Noteworthy Treatments for Brain Tumors Web site, August 1999. Schering-Plough announces FDA approval of TEMODAR(TM) (temozolomide) capsules for patients with refractory anaplastic astrocytoma: first new chemotherapy agent for brain tumors in 20 years. http://www.virtualtrials.com/temodar%5Cpress.cfm . Accessed 3 January 2013.
    1. Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001;1:13–19. - PubMed
    1. Mason WP, Cairncross JG. Drug insight: temozolomide as a treatment for malignant glioma—impact of a recent trial. Nat Clin Pract Neurol. 2005;1:88–95. - PubMed
    1. Sher DJ, Henson JW, Avutu B, et al. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol. 2008;88:43–50. - PMC - PubMed
    1. Vinjamuri M, Adumala RR, Altaha R, Hobbs GR, Crowell EB., Jr. Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients. J Neurooncol. 2009;91:221–225. - PubMed

Publication types

MeSH terms